The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines, today announced the election of its 2025 Board of Directors.
“I’m delighted to welcome these accomplished cell and gene therapy leaders to the ARM Board of Directors,” said Devyn Smith, ARM Board Chair and Chief Executive Officer of Arbor Biotechnologies. “Their expertise and passion will help ARM fulfill its mission of bringing transformative medicines to patients in need. I also want to express my gratitude to those Board members who are continuing their service and to those completing their tenures.”
The announcement comes as ARM kicks off its 2024 Cell & Gene Meeting on the Mesa, a gathering of 2,000 leaders in the cell and gene therapy sector. Eight new Board Directors will join 25 other Directors who will continue their service on the ARM Board in 2024, while seven Board directors are stepping off the Board.
“ARM’s Board of Directors plays an integral role in determining the strategic direction of ARM and the cell and gene therapy sector overall,” said ARM’s Chief Executive Officer Tim Hunt. “Our newest Board members reflect the full spectrum of ARM’s multistakeholder membership including biotechnology companies, patient advocates, research institutions, and strategic suppliers – all united in their efforts to deliver new treatments for the most devastating diseases.”
In addition to overseeing ARM’s work to convene the sector, enable the development of cell and gene therapies, and to enhance patient access, ARM’s Board provides strategic guidance on topics including ARM’s geographic expansion and maintaining the right balance for its multistakeholder membership.
ARM 2025 Board of Directors
*New to the Board for 2025
Faraz Ali, MBA – Chief Executive Officer, Tenaya Therapeutics
Robert Ang, MBBS, MBA – President and Chief Executive Officer, Vor Biopharma
Catherine Bollard, M.B.Ch.B, M.D. – Director of the Center for Cancer and Immunology Research, Children’s National Hospital and The George Washington University
Moya Daniels, MS – Chief Quality Officer, Savanna Biotherapeutics
Lisa Deschamps, MBA, BBA – Chief Executive Officer and Executive Board Member, AviadoBio
Debbie Drane – Senior Vice President, Strategic Projects, CSL Behring
*Matthew Durdy, MA, MBA – Chief Executive, Cell & Gene Therapy Catapult
*Anne-Virginie “AV” Eggimann, MS – Chief Regulatory Officer, Tessera Tx
*George Eastwood – Board Chair and Executive Director, Emily Whitehead Foundation
Miguel Forte, M.D., Ph.D. – Chief Executive Officer and Co-Founder, Kiji Therapeutics
Audrey Greenberg, CPA, MBA – Founder, Center for Breakthrough Medicines
Matt Kapusta, MBA – Chief Executive Officer, uniQure
*Sadik Kassim, Ph.D. – Chief Technology Officer & Chief Scientific Officer, Danaher Genomic Medicines
Brett Kopelan – Executive Director, debra of America
Ann Lee, Ph.D. – Chief Technical Officer, Prime Medicine
Anshul Mangal, J.D. – Co-Founder & President, Project Farma/Precision ADVANCE
Adora Ndu, PharmD, J.D. – Chief Regulatory Affairs Officer, BridgeBio
Susan Nichols – Chief Executive Officer, Propel Biosciences
Kinnari Patel, PharmD, MBA – President and Head of R&D and Chief Operating Officer, Rocket Pharma
Karah Parschauer, J.D. – Chief Legal Officer & Executive Vice President, Ultragenyx
Jacob Petersen – Senior Vice President, Head of Global Nucleic Acid Therapies, Novo Nordisk
Louise Rodino-Klapac, Ph.D. – Executive Vice President, Head of R&D, Chief Scientific Officer, Sarepta Therapeutics
Alberto Santagostino – Former Senior Vice President, Head of Cell & Gene Technologies Business Unit, Lonza
Laura Sepp-Lorenzino, Ph.D. – Executive Vice President & Chief Scientific Officer, Intellia Therapeutics
*Christy Siegel, PharmD – Senior Vice President & US Therapeutic Area Head, Immunology, Novartis
*Manny Simons, Ph.D., MBA – Chief Executive Officer & Co-Founder, Akouos; Senior Vice President, Gene Therapy, Eli Lilly & Co.
Bob Smith, MBA – Venture Partner, Orbimed
Devyn Smith, Ph.D. – Chief Executive Officer, Arbor Biotechnologies
Christopher Vann – Senior Vice President and Chief Operating Officer, Autolus Therapeutics
Richard Wilson, MBA – Senior Vice President, Primary Focus Lead, Genetic Regulation, Astellas Pharma
Kristin Yarema, Ph.D. – President and Chief Executive Officer, Poseida Therapeutics
*Ran Zheng – Chief Executive Officer, Landmark Bio
*Fyodor Urnov, Ph.D. – Director, Technology & Translation, Innovative Genomics Institute
